Multicenter Prospective Observational Study on Diaphragmatic Function Assessment by Ultrasound in Patients with Acute Respiratory Failure Receiving Non-invasive Mechanical Ventilation or High Flow Nasal Canula

NCT ID: NCT06892912

Last Updated: 2025-03-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-06-02

Study Completion Date

2026-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary goal of this study is to assess diaphragm function in patients with acute respiratory failure before and during the use of high-flow oxygen and/or non-invasive breathing support. The key question it seeks to answer is:

1\. How do ultrasound measurements of diaphragmatic function vary with different levels of breathing support in patients with acute respiratory failure? Participants with acute respiratory failure will undergo diaphragmatic ultrasound evaluation as part of their standard medical care at various levels of respiratory support.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Protocol for Assessment and Measurement of Diaphragmatic Ultrasound

Ultrasonographic Evaluation of the Diaphragm Protocol:

This protocol focuses on observing and evaluating diaphragmatic function in patients with acute respiratory failure who require non-invasive mechanical ventilation (NIMV) and/or high-flow nasal cannula (HFNC). The ultrasound measurements performed by researchers will be standardized to ensure consistency and accuracy in assessing diaphragmatic function.

Assessment of Diaphragmatic Thickness Collection of arterial blood gases is performed 1 hour after being on the clinician-selected pressure support (PS) level.

Cut-Off Points for Diaphragmatic Assessment Parameters

For the evaluation of diaphragmatic function in patients with acute respiratory failure requiring non-invasive mechanical ventilation (NIMV), the following cut-off points will be used:

Diaphragmatic Excursion:

Diaphragmatic excursion will be measured in centimeters using ultrasound in B-mode and M-mode.

Cut-Off Point: A diaphragmatic excursion of less than 1 cm will be considered indicative of severe diaphragmatic dysfunction, while an excursion greater than 2 cm will be interpreted as excessive diaphragmatic function.

Time to Maximum Inspiratory Amplitude:

This parameter will be measured in seconds from the start of inspiration until the diaphragm reaches its maximum amplitude.

Cut-Off Point: A time to maximum amplitude greater than 0.5 seconds will suggest compromised diaphragmatic function, while a time of less than 0.5 seconds will be deemed normal.

Diaphragmatic Thickening Fraction:

To evaluate diaphragmatic thickness, the following methodology will be implemented:

Patient Positioning:

Explain the procedure to the patient and/or family member. The patient should be positioned supine with the head of the bed elevated between 30 and 40 degrees.

Equipment Setup:

Select a high-frequency linear transducer (7-10 Megahertz) in B-mode. Position the probe in the right intercostal space, drawing an imaginary line between the anterior axillary line and the mid-axillary line, between the eighth and tenth right ribs.

The transducer must be positioned consistently in the same location for each measurement.

Identification of the Apposition Zone:

Locate the apposition zone of the diaphragm, which will appear as a three-layered structure: a central non-echoic layer (the diaphragm) surrounded by two parallel echogenic layers (the peritoneum and the diaphragmatic pleura).

Measurement of Thickness:

In M-mode, the thickness of the diaphragm will be evaluated, which varies according to the phase of the respiratory cycle, being greater during inspiration and less during expiration.

The sweep speed will be increased to obtain at least three consecutive thickening measurements on the screen. The image will be frozen, and three measurements will be taken during three different breaths to obtain an average.

During inspiration, it will be ensured that the thickness is greater, and the distance between the hyperechoic lines will be measured.

During expiration, the distance between the hyperechoic lines will be measured, ensuring that the thickness is less.

Measurement of Diaphragmatic Excursion:

To evaluate diaphragmatic excursion, the following methodology will be implemented:

Patient Positioning:

Explain the procedure to the patient and/or family member. The patient should be positioned supine with the head of the bed elevated between 30 and 40 degrees.

Equipment Setup:

A sector transducer (5-8 Megahertz) or a convex transducer (2-5 Megahertz) will be used in B-mode.

The probe will be positioned in the mid-clavicular line window, immediately below the costal margin, between the mid-clavicular line and the anterior axillary line. The ultrasound beam will be directed cephalically, perpendicular to the posterior third of the diaphragm.

The transducer must be positioned consistently in the same location for each measurement.

Ultrasound of the Diaphragmatic Dome Area:

Using a sector transducer in a cephalic position, the diaphragm will be insonated, adjusting the image so that M-mode is at a 90-degree angle to the dome of the diaphragm.

The sweep speed will be increased to obtain at least three consecutive excursions displayed on the screen. The image will be frozen, and three measurements will be taken during three different breaths to obtain an average.

Measurements of Diaphragmatic Function by Ultrasound

Calculation of Diaphragmatic Thickening Fraction:

This will be calculated by taking the thickening diameter during inspiration, subtracting the thickening diameter during expiration, dividing the result by the thickening diameter during expiration, and multiplying the result by 100%. The diaphragmatic thickening fraction, which varies depending on ventilation support, has reference values indicating diaphragmatic insufficiency (less than 20%) and values above 30%.

Calculation of Diaphragmatic Excursion:

Diaphragmatic excursion (DE, centimeters), inspiratory time (TPIA-dia, seconds), diaphragm contraction speed (DE/TPIA-dia, centimeters per second), and total time (Ttot, seconds) will be calculated in M-mode; diaphragmatic dysfunction will be defined as DE \< 1 cm or paradoxical movement.

Record the data in the corresponding format. Conduct the measurements at the selected flow levels of the high-flow nasal cannula.

The thickening fraction will be calculated using the formula:

((\\text{Thickness during Inspiration} - \\text{Thickness during Expiration}) / \\text{Thickness during Expiration} \\times 100%) Cut-Off Point: A thickening fraction of less than 20% will be considered indicative of diaphragmatic weakness, while a fraction greater than 30% will be deemed excessive.

These cut-off points will allow for a precise and objective assessment of diaphragmatic function, facilitating optimal titration of support pressure during non-invasive mechanical ventilation (NIMV) and thereby improving clinical outcomes in patients with acute respiratory failure.

Study Protocol:

The protocol begins with the admission of the patient with hypoxemic/hypercapnic respiratory failure. Support pressure levels (NIMV cohort) / flow (high-flow nasal cannula (HFNC) cohort) will be applied at the discretion of each center. Patients will be placed in a semi-sitting position at an angle of 30-40 degrees throughout the study. The first diaphragmatic measurement will be taken before the initiation of non-invasive mechanical ventilation (T0) without delaying the start of treatment. The second measurement will be taken 30 minutes after the start of NIMV/HFNC (T1), and the third will be taken 60 minutes after the start of NIMV/HFNC (T2). Measurements will include excursion (centimeters), time to maximum inspiratory amplitude (seconds), total respiratory cycle time (seconds), and diaphragmatic thickening fraction (ED, centimeters) (FTD%), as well as oxygen saturation (SpO2), exhaled tidal volume, respiratory rate, heart rate, and systolic, diastolic, and mean blood pressure at each time point (T0, T1, and T2).

The next measurement of hemodynamic variables (systolic, diastolic, mean blood pressure, heart rate) and respiratory variables (respiratory rate, SpO2) will be conducted one hour after identifying the optimal level of support pressure/flow (defined individually by each center) at which the patient will remain.

Summary of Ultrasonographic Diaphragm Assessment:

Non-Invasive Mechanical Ventilation (NIMV) Patient Cohort Time 0: Prior to the initiation of NIMV support. Time 1: 30 minutes after the initiation of NIMV. Time 2: 60 minutes after the initiation of NIMV.

High-Flow Nasal Cannula (HFNC) Patient Cohort Time 0: Prior to the initiation of HFNC support. Time 1: 30 minutes after the initiation of HFNC. Time 2: 60 minutes after the initiation of HFNC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiration Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with acute respiratory failure

Patients with acute respiratory failure (e.g., hypoxemic or hypercapnic) who require non-invasive mechanical ventilation or high-flow nasal canula.

Diaphragmatic ultrasound

Intervention Type OTHER

Sample:

Given the observational nature of the study, a convenience sample will be obtained from all patients admitted to the emergency services and/or ICU with respiratory failure over the course of 1 year.

Inclusion Criteria:

* Age ≥ 18 years
* Hypoxemic respiratory failure (SpO2 \< 88% - PaO2 \< 60 mmHg) or hypercapnic (PaCO2 \> 40)
* Need for NIMV and/or HFNC.

Exclusion Criteria:

* Neuromuscular disease
* Pregnancy
* Tracheostomy
* Rib fractures
* Cervical injuries
* Diaphragmatic paralysis
* Diaphragmatic malformations
* Hemodynamic instability
* Morbid obesity (BMI \> 35)
* Use of sedation and neuromuscular relaxants
* Pneumothorax or pneumomediastinum
* Poor acoustic window
* Critically ill patients with a prognosis of less than 24 hours of life
* Patients receiving palliative interventions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diaphragmatic ultrasound

Sample:

Given the observational nature of the study, a convenience sample will be obtained from all patients admitted to the emergency services and/or ICU with respiratory failure over the course of 1 year.

Inclusion Criteria:

* Age ≥ 18 years
* Hypoxemic respiratory failure (SpO2 \< 88% - PaO2 \< 60 mmHg) or hypercapnic (PaCO2 \> 40)
* Need for NIMV and/or HFNC.

Exclusion Criteria:

* Neuromuscular disease
* Pregnancy
* Tracheostomy
* Rib fractures
* Cervical injuries
* Diaphragmatic paralysis
* Diaphragmatic malformations
* Hemodynamic instability
* Morbid obesity (BMI \> 35)
* Use of sedation and neuromuscular relaxants
* Pneumothorax or pneumomediastinum
* Poor acoustic window
* Critically ill patients with a prognosis of less than 24 hours of life
* Patients receiving palliative interventions.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Hypoxemic respiratory failure (SpO2 \< 88% - PaO2 \< 60 mmHg) or hypercapnic (PaCO2 \> 40)
* Need for NIMV and/or HFNC.

Exclusion Criteria

* Neuromuscular disease
* Pregnancy
* Tracheostomy
* Rib fractures
* Cervical injuries
* Diaphragmatic paralysis
* Diaphragmatic malformations
* Hemodynamic instability
* Morbid obesity (BMI \> 35)
* Use of sedation and neuromuscular relaxants
* Pneumothorax or pneumomediastinum
* Poor acoustic window
* Critically ill patients with a prognosis of less than 24 hours of life Patients receiving palliative interventions.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Foro Internacional en Cuidado Crítico

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Carlos Andres Santacruz Herrera

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Carlos A Santacruz H, MD, PhD

Role: STUDY_DIRECTOR

Foro Internacional en Cuidado Crítico

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Carlos A Santacruz H, MD, PhD

Role: CONTACT

+57 318 8371125

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CBE03_2025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.